• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-13

  This study introduces a patient-specific gastric cancer assembloid system that integrates matched tumor organoids with stromal cell subpopulations, more accurately recapitulating the tumor microenvironment. The model demonstrates significant advantages for studying drug resistance, tumor heterogeneity, and personalized therapy development.

• Sunitinib in Precision Oncology: RTK Inhibition and ATRX-Def

  2026-05-13

  Explore Sunitinib’s role as a multi-targeted receptor tyrosine kinase inhibitor in precision oncology research. This article elucidates the practical impact of ATRX status on experimental design, offering actionable insights for apoptosis and cell cycle studies.

• Bestatin Enables Chemical Genetics Dissection of Jasmonate S

  2026-05-12

  This study demonstrates that bestatin, an aminopeptidase inhibitor, specifically activates jasmonate (JA) signaling and enables chemical genetic screening in Arabidopsis. The results provide new genetic tools and mechanistic insights for unraveling JA-regulated plant defense and development.

• Dual-Action p38α MAPK Inhibition: Mechanistic Insights from

  2026-05-12

  The referenced study reveals how specific kinase inhibitors, including those targeting p38α MAPK, not only block enzyme activity but also accelerate dephosphorylation of key regulatory sites by altering kinase conformation. This dual-action mechanism offers a new route for achieving greater specificity and efficacy in inflammation and apoptosis research.

• SNAI1–PIK3R2/p-EphA2 Axis Drives EMT and Stemness in TETs

  2026-05-11

  This study identifies SNAI1 as a central transcriptional driver of epithelial-mesenchymal transition (EMT) and cancer stem cell-like properties in thymic epithelial tumors (TETs), operating through the PIK3R2/p-EphA2 signaling axis. The findings highlight a mechanistically defined pathway that may inform future therapeutic strategies and experimental models for kinase-driven malignancies.

• Naloxone Hydrochloride: Applied Workflows for Opioid Researc

  2026-05-11

  Naloxone hydrochloride is revolutionizing opioid receptor antagonist research with reproducibility and precise workflow integration. This guide details actionable scenarios, troubleshooting strategies, and leverages new mechanistic insights for neural and behavioral studies.

• Biomimetic CaCO3 Nanoparticles Deliver IL-12 mRNA for GBM So

  2026-05-10

  Zhao et al. developed a biomimetic, cRGD-modified calcium carbonate nanoparticle system to deliver IL-12 mRNA across the blood-brain barrier, targeting glioblastoma and enabling ultrasound-induced necroptosis for enhanced immunotherapy. This platform demonstrates improved mRNA delivery, tumor targeting, and immune activation, highlighting a promising strategy for overcoming brain tumor therapeutic barriers.

• Mavorixafor Hydrochloride: Precision CXCR4 Antagonism in Tra

  2026-05-09

  Explore how Mavorixafor hydrochloride, a leading CXCR4 antagonist, empowers advanced translational research from rare immunodeficiencies to anti-HIV strategies. This article uniquely dissects its mechanism, assay optimization, and practical implications for vascular and immune cell migration studies.

• LDH Cytotoxicity Assay Kit: Precision in Cell Damage Quantif

  2026-05-08

  The LDH Cytotoxicity Assay Kit enables accurate cell cytotoxicity measurement by quantifying lactate dehydrogenase release, offering a non-radioactive alternative for apoptosis detection. Its robust design supports reproducible workflows in cancer research and nanomaterial biocompatibility assessment.

• E-64d: Precision Cysteine Protease Inhibition in Cell Death

  2026-05-08

  E-64d, a membrane-permeable cysteine protease inhibitor, enables precise modulation of calpain and cathepsin activity for apoptosis, lysoptosis, and neuroprotection research. By integrating insights from recent mechanistic breakthroughs and standardized workflows, this article empowers researchers to maximize reproducibility, troubleshoot pitfalls, and select optimal parameters for translational studies.

• DiR (DiIC 18 (7)): Optimized Cell Membrane Staining & Tracin

  2026-05-07

  DiR (DiIC 18 (7)) enables high-sensitivity, near-infrared membrane labeling for long-term cell tracking and advanced in vivo imaging. This article details best-practice protocols, troubleshooting, and workflow refinements inspired by the latest extracellular vesicle tracing research.

• Signal Amplification in Translational Neuroscience: Cy3 TSA

  2026-05-07

  This thought-leadership article explores how the Cy3 TSA Fluorescence System Kit is revolutionizing the detection of low-abundance biomolecules in neuroepigenetic research. We blend mechanistic insights from recent discoveries on olfactory receptor gene regulation with strategic guidance for translational researchers, offering actionable protocol parameters, competitive landscape analysis, and a forward-looking outlook on bridging molecular insights to clinical impact.

• Macrophage EV miR-660 Drives Breast Cancer via KLHL21/NF-κB

  2026-05-06

  This study elucidates how tumor-associated macrophage–derived extracellular vesicles (EVs) shuttle microRNA-660 to breast cancer cells, suppressing KLHL21 and activating the NF-κB pathway to promote metastasis. The findings highlight a novel intercellular communication mechanism that could inform future therapeutic targeting of breast cancer progression.

• Pazopanib Hydrochloride (SKU A8347): Reliable Solutions for

  2026-05-06

  This article provides scenario-driven, evidence-based guidance for integrating Pazopanib Hydrochloride (SKU A8347) into advanced cell viability and cytotoxicity assays. By addressing common laboratory challenges and supporting protocol decisions with quantitative data, it demonstrates how Pazopanib Hydrochloride ensures reproducible, high-quality results for cancer research teams.

• Pazopanib Hydrochloride (GW786034): Anti-Angiogenic Benchmar

  2026-05-05

  Pazopanib Hydrochloride (GW786034) is a potent multi-target receptor tyrosine kinase inhibitor validated for anti-angiogenic and anti-tumor activity. It features nanomolar inhibition of VEGFR, PDGFR, and FGFR, robust in vitro and in vivo efficacy, and clear protocol parameters for cancer research. Its role in renal cell carcinoma and soft tissue sarcoma is supported by quantitative evidence.

14486 records 1/966 page Next 12345 下5页 Last page